This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Lenacapavir a HIV-1 capsid inhibitor

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Lenacapavir a HIV-1 capsid inhibitor

  • is the first of a new class of drug called capsid inhibitors to be FDA-approved for treating HIV-1
  • is a novel, first-in-class, multistage, selective inhibitor of HIV capsid protein
  • blocks the HIV-1 virus' protein shell and interferes with essential steps of the virus' evolution
  • binds to the HIV-1 capsid to potently inhibits HIV-1 replication in vitro and in vivo (1)
    • in clinical studies, lenacapavir has demonstrated successful antiviral activity and adequate pharmacokinetic exposure for up to 6 months after a single subcutaneous injection (2)
    • by binding to two neighbouring subunits of the HIV capsid protein, lenacapavir interferes with their interactions essential for multiple phases of the viral replication cycle (1,2) and include:
      • capsid-mediated nuclear uptake of preintegration complexes,
      • virion production and proper capsid core formation
      • virus produced in the presence of lenacapavir displays improperly shaped capsids that can enter new target cells but cannot replicate

Reference:

  • Selyutina A, Hu P, Miller S, Simons LM, Yu HJ, Hultquist JF, Lee K, KewalRamani VN, Diaz-Griffero F. GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factors. iScience. 2021 Dec 9;25(1):103593
  • Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022 Jan 1;17(1):15-21.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.